Parabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business Updates
Presented updated Phase 1/2 data at ESMO Congress 2026 demonstrating a 72.2% objective response rate at the 32-week landmark and a favorable safety and tolerability profile for zolucatetide in desmoid tumorsReached alignment with the U.S. FDA on dose, regimen and trial design for upcoming PEDESTAL…